Pfizer Inc.

NYSE:PFE   3:59:57 PM EDT
-0.24 (-0.54%)
: $43.89 -0.06 (-0.14%)

Myovant Sciences And Pfizer Announce FDA Acceptance Of Supplemental New Drug Application For Myfembree For Management Of Moderate To Severe Pain Associated With Endometriosis

Published: 09/09/2021 12:21 GMT
Pfizer Inc. (PFE) - Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for Myfembree® for the Management of Moderate to Severe Pain Associated With Endometriosis.
Myovant Sciences Ltd - FDA Set a Target Action Date of May 6, 2022 for This Snda Under Prescription Drug User Fee Act.